JAMDA
Volume 10, Issue 3 , Page 211 , March 2009

Lubiprostone to Prevent Fecal Impaction

References 

  1. Morley JE. Hot topics in geriatrics. J Am Med Dir Assoc. 2008;9:613–616
  2. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: Systematic review. Am J Gastroenterol. 2005;100:936–971
  3. MacDonald KD, McKenzie KR, Henderson MJ, et al. Lubriprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol. 2008;295:L933–L940
  4. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on GI transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942–G947
  5. Patrick A, Epstein O. Review article: Gastroparesis. Aliment Pharmacol Ther. 2008;27:724–740
  6. Lacy BE, Levy LC. Lubiprostone A chloride channel activator. J Clin Gastroenterol. 2007;41:345–351
  7. Ginzburg R, Ambizas EM. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders. Expert Opin Drug Metab Toxicol. 2008;4:1091–1097

PII: S1525-8610(09)00003-6

doi: 10.1016/j.jamda.2008.12.055

JAMDA
Volume 10, Issue 3 , Page 211 , March 2009

Article Tools